{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:12:10Z","timestamp":1777317130671,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jhepr.2025.101618","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:25:48Z","timestamp":1760073948000},"page":"101618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trials"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-400X","authenticated-orcid":false,"given":"Thierry","family":"Verbinnen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkki","family":"Lathouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Augustyns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101618_bib1","first-page":"211","article-title":"Discovery and development of ARO-HBV\/JNJ-3989","author":"Wooddell","year":"2025","journal-title":"Trends Antivir Drug Develop"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101618_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101618_bib3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101618_bib4","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/nprot.2007.278","article-title":"A protocol for designing siRNAs with high functionality and specificity","volume":"2","author":"Birmingham","year":"2007","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101618_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101618_bib6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.cell.2012.10.036","article-title":"Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties","volume":"151","author":"Wee","year":"2012","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.jhepr.2025.101618_bib7","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101153","article-title":"Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2","volume":"38","author":"Sheu-Gruttadauria","year":"2019","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101618_bib8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101618_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective","volume":"28","author":"Carr","year":"2023","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.jhepr.2025.101618_bib10","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.jhepr.2025.101618_bib11","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1128\/JVI.77.21.11531-11535.2003","article-title":"Human immunodeficiency virus type 1 escape from RNA interference","volume":"77","author":"Boden","year":"2003","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101618_bib12","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1128\/JVI.79.11.7050-7058.2005","article-title":"Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region","volume":"79","author":"Wilson","year":"2005","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101618_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/JVI.79.2.1027-1035.2005","article-title":"Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches","volume":"79","author":"Gitlin","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2025.101618_bib14","unstructured":"FDA. Submitting next generation sequencing data to the division of antiviral products. In: US Depertment of Health and Human Services FaDAF, Center for Drug Evaluation and Research (CDER), editor. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/submitting-next-generation-sequencing-data-division-antiviral-products-guidance-industry-technical2019."},{"issue":"9","key":"10.1016\/j.jhepr.2025.101618_bib15","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1371\/journal.pgen.0020140","article-title":"Designing siRNA that distinguish between genes that differ by a single nucleotide","volume":"2","author":"Schwarz","year":"2006","journal-title":"Plos Genet"},{"issue":"22","key":"10.1016\/j.jhepr.2025.101618_bib16","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1093\/nar\/gkp835","article-title":"Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101618_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van Bommel","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2025.101618_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/gutjnl-2024-333026","article-title":"Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989","volume":"74","author":"Mak","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101618_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jhepr.2025.101618_bib20","series-title":"Liver concentrations of JNJ-73763989 in patients with chronic hepatitis B: the INSIGHT Study Panel 3 results","author":"Asselah","year":"2023"},{"issue":"1","key":"10.1016\/j.jhepr.2025.101618_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.122.001229","article-title":"Plasma and liver pharmacokinetics of the N-acetylgalactosamine short interfering RNA JNJ-73763989 in recombinant adeno-associated-hepatitis B virus-infected Mice","volume":"383","author":"Sandra","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101618_bib22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/0091270006293304","article-title":"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects","volume":"46","author":"Yan","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jhepr.2025.101618_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jhepr.2025.101618_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.jhepr.2025.101618_bib25","doi-asserted-by":"crossref","first-page":"eadg6265","DOI":"10.1126\/sciadv.adg6265","article-title":"An RNA-based system to study hepatitis B virus replication and evaluate antivirals","volume":"9","author":"Yu","year":"2023","journal-title":"Sci Adv"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:33:46Z","timestamp":1773830026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589555925003003"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101618","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trials","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101618"}}